RUTHERFORD, N.J. and RALEIGH, N.C., Sept. 24, 2014 (GLOBE NEWSWIRE) -- Cancer Genetics Inc. (Nasdaq:CGIX) ("CGI" or "the Company"), an emerging leader in DNA-based cancer diagnostics, today released an agenda for its upcoming Analyst Day, to be held Thursday, September 25 in Raleigh, North Carolina.
The event will offer updated information on the Company's portfolio of disease-focused proprietary genomic tests, and will provide a comprehensive overview of proprietary test development plans, technology development and validation, and progress with research collaborations. The Analyst Day will focus on the Company's tests for B-cell cancers, including chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL), as well as the Company's tests in kidney cancer and cervical cancer. In addition, Cancer Genetics will review recent updates related to its joint venture with Mayo Clinic, OncoSpire Genomics, and the incorporation of pharmacogenomics into molecular profiling of tumor systems.
Cancer Genetics' CEO Panna Sharma will open the event at 10 a.m. EDT. Other speakers from the Company will include Jane Houldsworth, Ph.D., Vice President of Research and Development (R&D); Banumathy Gowrishankar, Ph.D., Principal Scientist for R&D; and Scott Clark, Ph.D., Vice President of Scientific Development.
Gianrico Farrugia, M.D., director of Mayo Clinic's Center for Individualized Medicine, will provide an update on CGI's joint venture with Mayo Clinic, OncoSpire Genomics, with particular focus on multiple myeloma (MM).
Details for the event are as follows:
Date: Thursday, September 25, 2014
Time: 10 a.m. – 3 p.m. EDT
Location: Cancer Genetics Research Triangle Park (RTP) - 133 Southcenter Court, Suite 400, Raleigh, North Carolina 27560
Online: The live webcast will be available at http://ir.cancergenetics.com/company-and-portfolio-update.
About Cancer Genetics
Cancer Genetics Inc. (Nasdaq:CGIX) is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital, and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute.
Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that the transaction will not close or, if it closes, will not realize the currently anticipated benefits, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company's Form 10-K for the year ended December 31, 2013 and 10-Q for the quarter ended March 31, 2014 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.
CONTACT: Media Relations Paul Kuntz RedChip Companies, Inc. 800-733-2447, ext. 105 email@example.com Investor Relations Michael Rice LifeSci Advisors, LLC 646-597-6997Source:Cancer Genetics